

Remarks

Claims 1 to 75 were in the application as originally filed. However, two claims were mistakenly labeled “3.” Accordingly, the second “claim 3” has been deleted, and claim 76 has been added to recite the subject matter of the second “claim 3.”

The specification has been amended at pages 25 and 46 in order to correct inadvertent grammatical errors.

The specification has been amended multiple times by replacing empty text boxes, inadvertently introduced due to a font error, with the actual symbols. Support for these amendments can be found, for example, in priority application number 60/468,685.

The specification and claims 1 to 5 have been amended to include “N-alk” in the phrase: “the other alkyl optionally interrupted with O, S or N-alk” in order to correct an inadvertent translation error. Support for these amendments can be found, for example, on page 15, line 24 of the specification, in original claim 6, and in priority application number 60/468,685.

Claim 1 has been amended to correct inadvertent errors for the Y and Y1 value “–O-F₂-CHF₂” which now correctly reads as “O-CF₂-CHF₂”. Support for these amendments can be found, for example, on page 18, line 13 of the specification and in original claim 27.

Claim 1 has also been amended to include various substituents set forth in original dependent claims 2, 8, 14, 15, 16, and 47 to better and more properly reflect what Applicants have a right to claim as their invention.

Claims 1, 2, and 3 have been amended to delete phrases indicating that particular substituents are “optionally substituted” when such phrases are redundant in view of the later recitation in said claims that all such substituents *are* optionally substituted.

Claims 1 to 64, 71 to 73 and 75 have been amended in order to write these claims in appropriate U.S. claim format.

Claims 14, 39, 41, 42, 45, 46, 52, 54 and 61 have been amended to place them in independent form including adding the limitations from base claim 1.

Claims 12 and 13 have been amended to correct inadvertent typographical errors so that the values for R1 correctly read as “O” instead of “0”.

Claim 14 has been amended to correct the inadvertent typographical error for the substituent "R9b" wherein the "b" was omitted.

Claim 43 has been amended to more clearly indicate that the specified radicals are values for -A2-B2-Y2. Support for this amendment can be found, for example, on page 26, lines 23 to 27 and page 28, line 2 of the specification.

Claim 52 has been amended to correct inadvertent typographical errors for the substituents "Y2A" and "Y2CA" which now correctly read as "Y2C".

Claim 57 has been amended to correct the inadvertent typographical error in the subscript for "C3-C-C₆" which now correctly reads as "C₃-C₆". Claim 57 has also been amended to delete redundant language relating to the isomers.

No new matter has been added by these amendments.

As presently amended, claims 1 to 76 are pending in this application.

Entry of the foregoing amendments and consideration of the remarks are respectfully requested.

The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment to Deposit Account No. 18-1982.

Respectfully submitted,

August 17, 2006

Date


Kelly L. Bender, Reg. No. 52,610
Attorney for Applicant

sanofi-aventis US LLC
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (610) 889-8995
Telefax (908) 231-2626

Sanofi-Aventis Docket No. FRAV2003/0002 US NP